MS-DETECT: MSCopilot® による多発性硬化症の進行の早期検出 (MS-DETECT)
The study aims to evaluate MSCopilot® Detect, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS).
The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Worsening (RAW) or Progression Independent of Relapses (PIRA). The study also aims to assess the safety, usability, and satisfaction of the solution.
A secondary objective is to determine MSCopilot® Detect's ability to provide early detection of disease changes and predict changes in Expanded Disability Status Scale (EDSS) scores in more patients.
Exploratory objectives include evaluating the relationship between MSCopilot® Detect composite and individual scores and other biomarkers such as MRI, soluble glial fibrillary acidic protein (sGFAP), and soluble neurofilament light chain (sNfL).
Patients will be able to download the free MSCopilot® Detect app. They will participate in 1 inclusion visit and 3 follow-up visits, scheduled at 6 months, 12 months, and 18 months (an additional visit at 24 months may be scheduled if necessary). Every 3 months, patients will complete validated questionnaires regarding MS symptoms and quality of life and participate in digital tests designed to monitor MS symptom progression.
The study will include 336 MS patients and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
California
-
San Diego、California、アメリカ、92093
- Jennifer Graves
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30327
- Joash Lazarus Sr.
-
-
Illinois
-
Northbrook、Illinois、アメリカ、60062
- Daniel Wynn
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46256
- Craig E. Herrman
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70121
- Jennifer Feng
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- Robert Naismith
-
-
Ohio
-
Columbus、Ohio、アメリカ、43235
- Aaron Boster
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- Gabriel Pardo
-
-
Oregon
-
Portland、Oregon、アメリカ、97239-3098
- Vijayshree Yadav
-
-
Texas
-
Austin、Texas、アメリカ、78712
- Leorah Freeman
-
-
-
-
-
Florence、イタリア
- Emilio Portaccio
-
Foggia、イタリア
- Emanuele D'Amico
-
Milan、イタリア
- IRCCS Ospedale San Raffaele
-
-
-
-
-
Burnaby、カナダ
- Galina Vorobeychik
-
Ottawa、カナダ
- Mark Freedman
-
Toronto、カナダ
- St. Michael's Hospital
-
Vancouver、カナダ
- Robert Carruthers
-
-
-
-
-
Girona、スペイン
- Gary Álvarez Bravo
-
Madrid、スペイン
- University Hospital San Carlos
-
Madrid、スペイン
- Enric Monreal
-
Málaga、スペイン
- Ana Alonso
-
Oviedo、スペイン
- Miguel Llaneza
-
Zaragoza、スペイン
- Jesùs Martin
-
-
-
-
-
Esbjerg、デンマーク
- University Hospital of Southern Denmark
-
Glostrup Municipality、デンマーク
- Finn Sellebjerg
-
Viborg、デンマーク
- Sivagini Prakash
-
-
-
-
-
Bayreuth、ドイツ
- Boris-Alexander Kallman
-
Dresden、ドイツ
- Universitätsklinikum Carl Gustav Carus
-
Erbach im Odenwald、ドイツ
- Rupert Knoblich
-
-
-
-
-
Lille、フランス
- Hôpital Roger Salengro
-
Lomme、フランス
- Cécile Donzé
-
Marseille、フランス
- Adil Maarouf
-
Nice、フランス
- Mikael Cohen
-
Rouen、フランス
- Bertrand Bourre
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adult patients living with RRMS or SPMS, aged 30 to 65
- EDSS score between 2.5 to 6.5 points
- With a disease duration > 5 years
- Clinically stable during the last 3 months before inclusion (no relapses, no disability progression)
- No change in the DMT* during the last 3 months before inclusion
- Receiving optimal symptomatic treatments at baseline (clinician's judgment)
- Owns a personal smartphone which mobile operating system is above 14 for IOS (iPhone) and 8 for Android included with a good internet connexion
- Able to use a smartphone
- Able to read language in wich the mobile application is available and able to understand pictograms.
- Applicable to patients enrolled in France only: affiliated to a social security system.
Exclusion Criteria:
- Medically unstable conditions that may hinder patient's ability to comply with the study procedures
- Inability to use a smartphone or MSCopilot® Detect application
- Patient with corrected visual acuity less than 4/10 (Monoyer) or 20/50 (Snellen at 20 feet) or +0,4 (LogMAR)
- Pregnancy and nursing women
- Persons under guardianship or curatorship
- Current drugs or/and alcohol abuse that could influence performance on the tests (clinician's judgment)
- Patients have participated in another clinical study within the previous 30 days of screening or are currently participating in another study that, in the opinion of the Investigator, might interfere with the patient's full participation in the study or confound the assessment of the patient or outcome of the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:MSCopilot® Detect
Performance of digital tests and standard test in clinic at D0, M6, M12, M18 and M24 (if applicable) Use of MSCopilot® Detect at-home in between visits during 18 or 24 months (if applicable) |
MSCopilot® Detect includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to fatigue and Multiple Sclerosis quality of life |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To evaluate MSCopilot® Detect individual scores and/or composite scores sensitivity to detect disability worsening based on revised-MSFC scores.
時間枠:Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
|
The discriminatory ability of the MSCopilot® Detect application in detecting clinically meaningful worsening (disability worsening) based on the revised-MSFC will be evaluated using the Area Under the ROC Curve (AUC) method. Confidence intervals will also be estimated. The minimum significant AUC value will be set at >0.67, and Confidence Intervals will be calculated. Sensitivity and specificity will also be determined. To validate the estimated AUC values and cutoffs generated by the MSCopilot® Detect application, a train/test set will be utilised. |
Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To evaluate MSCopilot® Detect individual scores and/or composite scores sensitivity to detect disability worsening based on EDSS.
時間枠:Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
|
The study will evaluate the sensitivity, specificity, concordance, and accuracy of the MSCopilot® Detect application in predicting confirmed disability worsening (CDW) at 24 weeks as also captured by the EDSS, using a contingency table. We will also generate time series box plots of MSCopilot® Detect individual scores and/or composite scores based on the patient progression status (determined by EDSS), using both intra-patient and inter-patient visualisation. |
Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
|
|
To evaluate MSCopilot® Detect individual scores and/or composite scores sensitivity to detect disability worsening earlier than the EDSS.
時間枠:Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
|
The time to progression-free events based on EDSS and MSCopilot® Detect individual scores and/or composite scores will be estimated with a Kaplan-Meier method (Log-rank test for comparison). Univariate and multivariate survival models (e.g. Cox or Anderson-Gill survival model), will be used to estimate Hazards Rates (HRs), if relevant. Proportions of disability worsening based on MSCopilot® Detect composite or individual scores and worsening based on the EDSS 24-week CDW will be compared for each timepoint. Time series boxplot of MSCopilot® Detect individual scores and/or composite score according to the patient disability worsening (by EDSS) intra-patient and inter-patient. |
Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
|
|
To evaluate MSCopilot® Detect individual and/or composite scores ability to detect disease progression in absence of a relapsing activity (PIRA).
時間枠:Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
|
Proportion of patients with PIRA (progression independent of relapses) based either on EDSS 24-week CDP compared to the proportion of patients with PIRA based on MSCopilot® Detect composite or individual scores progression status. |
Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
|
|
To evaluate MSCopilot® Detect individual scores and/or composite scores ability to detect MSFC changes over time.
時間枠:Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
|
Slopes parameters will be computed using a mix model to characterize the change from baseline in MSCopilot® Detect individual and/or composite scores and revised-MSFC scores over time. The association between these slopes parameters will be assessed using correlation coefficient. |
Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
|
|
To measure MSCopilot® Detect individual scores and/or composite scores association with the clinical scores.
時間枠:Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
|
The association between digital and clinical scores will be studied with correlation coefficient calculated between:
|
Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
|
|
To assess reproducibility of MSCopilot® Detect individual scores and/or composite scores between in-clinic and at-home digital tests.
時間枠:At home (Day 1, Month 6+1 day, Month 12 + 1 day, Month 18-1 day and Month 24-1 day (if applicable)) and in-clinic ((Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable))
|
Intraclass correlation coefficient (ICC) between MSCopilot® Detect individual scores and/or composite score at home and in-clinic. |
At home (Day 1, Month 6+1 day, Month 12 + 1 day, Month 18-1 day and Month 24-1 day (if applicable)) and in-clinic ((Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable))
|
|
To assess reliability of MSCopilot® Detect individual scores and/or composite scores at-home over time.
時間枠:Day 0 versus Month 6, Month 6 versus Month 12, Month 12 versus Month 18, Month18 versus Month 24 (if applicable) AND Day 0 to Month 18 or Day 0 to Month 24 (if applicable) and Day 0 to Month 15 or Day 0 to Month 21 (if applicable) at home.
|
Intraclass correlation coefficient (ICC) of MSCopilot® Detect individual scores and/or composite score at home with a maximum paired time point of 6 months. ICC of MSCopilot® Detect individual scores and/or composite score at home will over time. |
Day 0 versus Month 6, Month 6 versus Month 12, Month 12 versus Month 18, Month18 versus Month 24 (if applicable) AND Day 0 to Month 18 or Day 0 to Month 24 (if applicable) and Day 0 to Month 15 or Day 0 to Month 21 (if applicable) at home.
|
|
To evaluate Patient QoL (Multiple Sclerosis Impact Scale: MSIS-29 and Modified Fatigue Impact Scale - 5-item version: MFIS-5) and their association with MSCopilot® Detect individual and composite scores.
時間枠:Throughout the study between in clinic visit, an average of 24 months
|
Analysis of MSIS-29 and MFIS-5 questionnaires: Descriptive analysis of questionnaire scores over time. Comparison of Patient QoL between patients with and without a confirmed disability worsening Correlation between MSCopilot® Detect individual and/or composite score at home and Questionnaires scores (MSIS29 and MFIS-5). Sensitivity, specificity, concordance, and accuracy will be evaluated between clinically meaningful change of MSCopilot® Detect application (individual and composite scores) and questionnaires (MSIS29 and MFIS-5). Proportions comparison of patients with a clinically meaningful change will be assessed between MSCopilot® Detect application (individual and composite scores) and questionnaires (MSIS29 and MFIS-5). Clinically meaningful change for questionnaires: MSIS-29: 8-point change compared to baseline. MFIS-5: 4-point change compared to baseline. |
Throughout the study between in clinic visit, an average of 24 months
|
|
To evaluate the ability of MSCopilot® Detect individual scores and/or composite score to discriminate between a relapse and a momentary disability worsening (+1 point EDSS score for an initial EDSS <5,5; +0.5 point for an initial EDSS ≥5.5).
時間枠:Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
|
Descriptive analysis: MSCopilot® Detect individual and/or composite score profiles, between relapse and a momentary disability worsening patient. Annualized Relapse Rate (ARR) calculation. Logistic regression to estimate Area under ROC Curve (i.e. discriminatory power). |
Throughout the study at each hospital visit: Day 0, Month 6, Month 12, Month 18 and Month 24 (if applicable)
|
|
To evaluate MSCopilot® Detect Safety
時間枠:Throughout the study between in clinic visit, an average of 24 months
|
Descriptive analysis of the number of Adverse Events related to MSCopilot® Detect will be reported. |
Throughout the study between in clinic visit, an average of 24 months
|
|
To evaluate MSCopilot® Detect Adherence
時間枠:Throughout the study between in clinic visit, an average of 24 months
|
Descriptive analysis of the mobile application's adherence data (number of completed questionnaires, number of performed tests, number of performed sessions, etc.) |
Throughout the study between in clinic visit, an average of 24 months
|
|
To assess the satisfaction and user experience with the MSCopilot® Detect smartphone application and the MSCopilot® Detect web dashboard.
時間枠:Every 3 months for about 24 months
|
Descriptive analysis over the course of the study of the answers to the patient satisfaction and user experience questionnaires related to the use of the MSCopilot® Detect smartphone application. |
Every 3 months for about 24 months
|
|
To assess the satisfaction and user experience with the MSCopilot® Detect web dashboard.
時間枠:Every 6 months for about 24 months
|
Descriptive analysis over the course of the study of the answers to physician satisfaction & user experience questionnaires relative to the use of the MSCopilot® Detect web dashboard. |
Every 6 months for about 24 months
|
|
To describe the evolution of MSCopilot® Detect individual scores and/or composite scores at-home over time.
時間枠:Throughout the study between in clinic visit, an average of 24 months
|
The time to progression-free events based on MSCopilot® Detect individual scores and/or composite scores will be estimated with a Kaplan-Meier method (Log-rank test for comparison). Univariate and multivariate survival models (e.g. Cox or Anderson-Gill survival model), will be used to estimate Hazards Rates (HRs), if relevant. Cumulative proportions of disability worsening based on MSCopilot® Detect composite or individual scores for each timepoint. Time series boxplot of MSCopilot® Detect individual scores and/or composite score according to the patient disability worsening (by MSCopilot® Detect) using both intra-patient and inter-patient visualisation. |
Throughout the study between in clinic visit, an average of 24 months
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- MS-DETECT
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。